Erleva 150mg Tablet
By Erleva
Rx
30 Tablet in a Strip

Composition
Erlotinib(150mg)

Manufacturer - Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals Limited, B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai – 400 026.

Expires on or after
April, 2026

liver
When it comes to using Erleva 150mg Tablet for patients with liver disease, caution is advised. It is important to consult with your doctor before starting treatment with this medication. Some patients with liver disease may require a dose adjustment when taking Erleva 150mg Tablet. While limited information is available on the use of this tablet in patients with liver issues, it is noted that no dose adjustment is generally recommended for those with mild to moderate liver disease. Always seek guidance from your healthcare provider to ensure the safe and appropriate use of Erleva 150mg Tablet.

kidney
Erleva 150mg Tablet is safe for patients with kidney disease. No dose adjustment needed. Not recommended for those with severe kidney disease.

alcohol
Consult your doctor when consuming alcohol with Erleva 150mg Tablet.

driving
It is not clear if Erleva 150mg Tablet affects driving ability. Avoid driving if you notice any symptoms that impact focus or reaction time.

pregnancy
Erleva 150mg Tablet is not safe to use during pregnancy due to the risk it poses to the developing baby. However, in rare life-threatening situations, a doctor may prescribe it if benefits outweigh risks. Consult your doctor before use.

breastfeeding
Erleva 150mg Tablet may not be safe during breastfeeding, as there is a risk of the drug passing into breastmilk and potentially harming the baby. It is recommended to consult a doctor before using this medication while breastfeeding.
Habit Forming | No |
Chemical Class | Quinazoline Derivative |
Therapeutic Class | - |
Action Class | Tyrosine kinase inhibitors |
₹5750
Inclusive of all taxes
Content verified by

Dr. Archana Prabhakar
MBBS, M.Med (Family Medicine)
Last update on 11-Feb-2025